BriaCell Therapeutics Corp.

BCT.TO·Toronto·Healthcare

Compare

4.8800−0.4800 (−8.96%)today

At close: Oct 16, 3:58 PM EDT · May be delayed up to 15 min · CAD

Key statistics

Previous close5.3600

Open5.4100

Day range4.80005.4100

52-week range3.680020.4000

Off day high−9.80%

Off 52-week high−76.08%

Volume15.46K

Avg. volume (3M)6.82K

Market cap42.45M

EPS (TTM)-1.39

Forward P/E-9.04

P/E ratio (TTM)—

Dividend yield—

Beta (5Y)1.51

Shares outstanding8.70M

Short interest0.15% of float

Earnings dateJun 12, 2025 (est.)

Analyst target—

Profit margin0.00%

Related companies

Compare ›

What visitors to BCT.TO's page also look at.

Company	Mkt cap	Price	Today
EUPRAXIA PHARMACEUTICALS INCEPRX.TO	617.79M	9.35	−2.91%
MEDICENNA THERAPEUTICS CORPMDNA.TO	41.54M	0.4500	+2.27%
MEDEXUS PHARMACEUTICALS INCMDP.TO	153.99M	4.9000	+1.87%
SERNOVA BIOTHERAPEUTICS INCSVA.TO	43.43M	0.1150	0.00%
HLS THERAPEUTICS INCHLS.TO	126.83M	4.1000	−0.97%

From the 4Conservative instruments index: what each company does (its business description), its industry, size, headquarters and the markets it serves; and from a year of daily prices, which move together. Prices may be delayed up to 15 min.

Latest news

All BCT.TO news ›

Markets Daily·Oct 8Negative

BriaCell Therapeutics (CVE:BCT) Stock Price Down 3.8% – Here’s What Happened

BriaCell Therapeutics Corp. (CVE:BCT – Get Free Report)’s stock price fell 3.8% during mid-day trading on Tuesday. The stock traded as low as C$10.60 and last traded at C$10.60. Approximately 3,402 shares were traded during mid-day…

The Manila Times·Oct 6Positive

BriaCell and BriaPro to Present Four Posters at SITC 2026 Annual Meeting

Presentation details are listed below. Title: Development of BP-80, a soluble CD80 dimer (CD80-Fc) for cancer treatment Date: Friday, Nov. 6, 2026 Title: Molecular design of CD80 variants with increased affinity for PD-L1 and wild-type or…

From articles in the 4Search news index.

In the news

2mentions in 30 days

1with it in the headline

Mixedsentiment

Most coverage from

stocktitan.net1
themarketsdaily.com1

Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 2 articles, not a forecast.

About

Profile ›

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the Univer…

SectorHealthcare

IndustryBiotechnology

Chief executiveWilliam V. Williams FCPA, M.D.

HeadquartersWest Vancouver, BC, Canada

Websitebriacell.com

Earnings

Reported EPS
Estimate

Next report: Thu, Jun 12, 2025 (estimated)

Quarterly results

Financials ›

Revenue
Net income

Prices may be delayed up to 15 min. Not investment advice.

Track record

Leaderboard ›

Days on the list	30 d	1 yr	Best
Trending	0	0	—

Not eligible for Gainers, Losers, Most active (U.S. stocks worth $2 billion or more only).

Not eligible for Small-cap gainers, Aggressive small caps (U.S. stocks worth under $2 billion only).

Not eligible for Growth tech (U.S. technology stocks only).

Not eligible for Undervalued large caps (U.S. stocks worth $10 billion or more only).

A day counts when it ranked in the top 25 of a list. Tracked since Oct 10, 2026.

Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4Conservative index. Terms of use.